An improved technique for spinal fusion including administration of an HMG-CoA reductase inhibitor to the fusion site. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a noncompressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.

 
Web www.patentalert.com

< Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1

< Contact coating of prostheses

> GPE analogs and peptidominetics

> Therapeutic and diagnostic tools for impaired glucose tolerance conditions

~ 00262